Regulation
Why Cannabis Laws and Cannabis Science Differ
Add MyCannabis.com to your preferred sources on Google
Cannabis can be described as a drug, a medicine, a controlled substance, or a consumer product. Those labels often appear to compete with one another, as though choosing one settles what the plant is and how society should treat it. In reality, they answer different questions.
A new essay by Pierre-Arnaud Chouvy, published in the International Journal of Drug Policy, examines the distinction between scientific definitions of drugs and legal classifications such as narcotic drugs.1 Its central argument offers a useful way to understand cannabis: biological effects, regulatory status, and social judgments should not be mistaken for the same thing.
This is a conceptual analysis, not a clinical trial or a new finding about cannabis safety. Its value lies in explaining why familiar words can create unfamiliar confusion. For consumers, clinicians, and policymakers, separating these meanings makes it easier to ask the questions that actually matter.
What Makes Cannabis a Drug?
In everyday conversation, calling something a drug often implies intoxication, addiction, or illegality. Pharmacology uses the word much more broadly. As the essay explains, a drug can be an externally introduced chemical substance, excluding nutrients or essential dietary ingredients, that produces a biological effect.
Within that framework, being a drug is not an accusation. The category includes substances used therapeutically as well as substances consumed for other purposes. It describes biological activity rather than whether a government permits a particular use.
Chouvy also discusses a narrower neuroscientific definition focused on psychotropic substances, meaning substances that act on the central nervous system and modify mental processes. Cannabis appears alongside alcohol, nicotine, caffeine, opioids, and psychedelics as an example within this broader discussion.
Grouping these substances together does not mean their effects or dangers are equivalent. It means they share a relevant characteristic within a particular scientific framework. A useful category identifies something its members have in common without erasing the differences between them.
Being a Drug Does Not Mean Being Addictive
The essay argues that addiction is not a defining requirement for membership in the scientific category of drugs. Addiction can involve behaviors, while substance exposure does not automatically produce addiction in every person.
That distinction should improve precision rather than diminish concern. Whether a substance is a drug and whether a pattern of use creates dependence are separate questions. Cannabis policy becomes less informative when the first is treated as an automatic answer to the second.
What Does Narcotic Mean in Cannabis Law?
The word narcotic creates another layer of confusion. In the international legal framework examined by Chouvy, membership in the relevant category follows institutional designation and scheduling. It is not established through one shared biological property that defines every scheduled substance.
The essay highlights the 1961 Single Convention on Narcotic Drugs, which defines its use of the word drug by reference to substances in specified schedules. The 1971 Convention on Psychotropic Substances similarly establishes its category through scheduled lists. These legal meanings should not be assumed to match scientific terminology.
Consequently, answering whether cannabis is a narcotic requires identifying the context. A treaty, national statute, medical discussion, and ordinary conversation may use the term differently. A label without its governing framework can imply more than it explains.
The following distinctions are drawn entirely from the essay:
| Term or Framework | Basis of Classification | Key Distinction |
|---|---|---|
| Drug in pharmacology | Externally introduced chemical substances producing biological effects, excluding nutrients and essential dietary ingredients | Does not require intoxication or illegality |
| Drug in neuroscience | Psychotropic action on the central nervous system that modifies mental processes | A narrower scientific category |
| Narcotic drug in the treaty framework | Institutional designation through scheduling | Legal membership differs from scientific definition |
| Drug in ordinary usage | Variable meanings and social associations | May carry connotations of danger, addiction, or illegality |
Legal Classification Can Use Science Without Becoming Science
Separating law from biology does not mean scheduling decisions ignore evidence. Scientific assessments can inform regulation, even though the legal category is ultimately established through an institutional process.
A recent WHO update on international scheduling decisions illustrates that relationship. In March 2026, the United Nations Commission on Narcotic Drugs endorsed controls on two potent synthetic opioids and the synthetic cannabinoid MDMB-FUBINACA following WHO recommendations.
WHO evaluates evidence including pharmacology, toxicology, dependence potential, and therapeutic value before making recommendations. The Commission makes the scheduling decision. Scientific evaluation and legal designation therefore interact without becoming interchangeable.
For cannabis discussions, the practical lesson is to specify the substance being assessed. A dangerous synthetic cannabinoid should not become a shortcut for describing every cannabis product. Equally, the existence of therapeutic cannabinoid applications cannot establish that every product marketed under a cannabis label is medically beneficial.
Why Cannabis Labels Shape Consumer Expectations
Legal and commercial categories also influence what people expect from a product. Something sold in a clinic may communicate therapeutic legitimacy. Something sold beside ordinary wellness products may suggest everyday safety. Neither setting, by itself, establishes clinical effectiveness.
Recent MyCannabis coverage of how CBD regulations shape consumer use explores how different regulatory systems organize purchasing channels and consumer expectations. The same ingredient can acquire different social meanings depending on where and how people obtain it.
This creates a policy challenge beyond deciding whether access is permitted. Regulators also influence the assumptions surrounding access. Medical positioning needs clear distinctions between approved therapies and other products. Consumer positioning needs accurate information that prevents familiarity from being mistaken for proof of safety.
Legalization Changes Rules, Not Molecular Properties
If lawmakers change the permitted activities surrounding cannabis, the substance does not acquire a different molecular identity at that moment. What changes directly is the legal framework governing it.
Over time, reform can change the products people encounter, the information available to them, and patterns of use. Those changes may affect outcomes, but they must be measured. A legal change alone cannot establish either improved health or worsening harm.
Better Cannabis Risk Questions Go Beyond Labels
The European Drug Report 2026 cannabis assessment demonstrates why product details matter. It identifies increasing product diversity and potency as complications for evaluating harms, and highlights concerns involving high-potency extracts, edibles, and emerging semi-synthetic cannabinoids.
Those distinctions are more useful than treating cannabis as one uniform exposure. A category can identify the general subject while remaining too broad to explain an individual product or pattern of consumption.
Readers evaluating a cannabis claim can ask:
- Which substance, formulation, and dose does the evidence concern?
- Does the claim describe a legal status, a biological effect, or a proven treatment?
- Were the findings observed in people, animals, or laboratory systems?
These questions help prevent two familiar mistakes: dismissing a possible treatment because it belongs to a stigmatized category, and assuming a marketed product works because it borrows the language of medicine.
Clearer Language Can Support Better Cannabis Research
Terminology also matters for evidence generation. MyCannabis recently examined barriers to rigorous cannabis research, including restrictive rules, product variability, and stigma. These obstacles show why legal access and research readiness are different achievements.
Clearer definitions cannot resolve funding shortages or inconsistent formulations. They can, however, help researchers specify what they administered and help readers understand how far a result extends. Evidence about one preparation should not silently become evidence about everything called cannabis.
The broader importance of language also appears in the 2025 Global Health Matters discussion, From Cannabis to Kush, which explores how language shapes substance-use policy.
Chouvy does not offer a formula for legalization or establish that cannabis is harmless. His contribution is a clearer starting point. Scientific properties, legal permissions, and moral judgments deserve separate examination. For cannabis, that means replacing arguments driven by labels with questions that evidence and policy can actually answer.
References:
1 Chouvy, P.-A. (2026). Drug and narcotic drug: Scientific definition, legal stipulation, and terminological clarification. International Journal of Drug Policy, 157, Article 105522. https://doi.org/10.1016/j.drugpo.2026.105522
